JP2010531304A - 抗悪性腫瘍活性を有するｐｆｋｆｂ３阻害物質ファミリー - Google Patents

抗悪性腫瘍活性を有するｐｆｋｆｂ３阻害物質ファミリー Download PDF

Info

Publication number
JP2010531304A
JP2010531304A JP2010513237A JP2010513237A JP2010531304A JP 2010531304 A JP2010531304 A JP 2010531304A JP 2010513237 A JP2010513237 A JP 2010513237A JP 2010513237 A JP2010513237 A JP 2010513237A JP 2010531304 A JP2010531304 A JP 2010531304A
Authority
JP
Japan
Prior art keywords
group
hydrogen atom
alkyl
chemical formula
aralkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010513237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010531304A5 (enExample
Inventor
チェスニー ジェイソン
オー トレント ジョン
テラン スチェッタ
クレム ブライアン
メイアー ジェイソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Louisville Research Foundation ULRF
Original Assignee
University of Louisville Research Foundation ULRF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Louisville Research Foundation ULRF filed Critical University of Louisville Research Foundation ULRF
Publication of JP2010531304A publication Critical patent/JP2010531304A/ja
Publication of JP2010531304A5 publication Critical patent/JP2010531304A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010513237A 2007-06-18 2008-06-18 抗悪性腫瘍活性を有するｐｆｋｆｂ３阻害物質ファミリー Pending JP2010531304A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93603007P 2007-06-18 2007-06-18
PCT/US2008/007594 WO2008156783A2 (en) 2007-06-18 2008-06-18 Family of pfkfb3 inhibitors with anti-neoplastic activities

Publications (2)

Publication Number Publication Date
JP2010531304A true JP2010531304A (ja) 2010-09-24
JP2010531304A5 JP2010531304A5 (enExample) 2011-07-28

Family

ID=39735477

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010513237A Pending JP2010531304A (ja) 2007-06-18 2008-06-18 抗悪性腫瘍活性を有するｐｆｋｆｂ３阻害物質ファミリー

Country Status (5)

Country Link
US (1) US8088385B2 (enExample)
EP (1) EP2167058B1 (enExample)
JP (1) JP2010531304A (enExample)
AU (1) AU2008266856A1 (enExample)
WO (1) WO2008156783A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512398A (ja) * 2012-03-29 2015-04-27 アドヴァンスト キャンサー セラピューティクス エルエルシーＡｄｖａｎｃｅｄ Ｃａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ Ｐｆｋｆｂ２阻害剤および抗癌治療法としての使用方法

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
MX2010007419A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
KR101763656B1 (ko) 2009-06-29 2017-08-01 인사이트 홀딩스 코포레이션 Ｐｉ3ｋ 저해물질로서의 피리미디논
EP2525790B1 (en) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
TW201130842A (en) * 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011103557A1 (en) * 2010-02-22 2011-08-25 Advanced Cancer Therapeutics, Llc Small molecule inhibitors of pfkfb3 and glycolytic flux and their methods of use as anti-cancer therapeutics
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
ES2608474T3 (es) 2010-04-22 2017-04-11 Vertex Pharmaceuticals Incorporated Proceso de producción de compuestos indol cycloalkylcarboxamido
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
WO2011161201A1 (en) 2010-06-22 2011-12-29 Kancera Ab Bisarylsulfonamides useful as kinase inhibitors in the treatment of inflammation and cancer
WO2012035171A2 (en) 2010-09-17 2012-03-22 Kancera Ab New compounds
EP3660016A1 (en) 2010-12-20 2020-06-03 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
GB201103762D0 (en) 2011-03-07 2011-04-20 Vib Vzw Means and methods for the treatment of neurodegenerative disorders
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
US9492418B2 (en) 2011-05-10 2016-11-15 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibitors of PFKFB3 for cancer therapy
RU2477723C2 (ru) 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
GB201112145D0 (en) 2011-07-15 2011-08-31 Vib Vzw Means and methods for the treatment of pathological angiogenesis
PT3513793T (pt) 2011-09-02 2021-05-10 Incyte Holdings Corp Heterociclilaminas como inibidores de pi3k
BR112014015607A2 (pt) 2011-12-22 2017-06-13 Kancera Ab composto
US10000449B2 (en) 2011-12-22 2018-06-19 Kancera Ab Bisarylsulfonamides useful in the treatment of inflammation and cancer
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
LT2925757T (lt) 2012-11-19 2017-12-27 Novartis Ag Junginiai ir kompozicijos, skirti parazitinių ligų gydymui
SG10202103278TA (en) 2013-10-14 2021-04-29 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
ES2670550T3 (es) 2013-10-14 2018-05-30 Eisai R&D Management Co., Ltd. Derivados de quinolina selectivamente sustituidos
ES2885181T3 (es) 2014-04-15 2021-12-13 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
GB201407693D0 (en) * 2014-05-01 2014-06-18 Univ Montfort Compound
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
SG10201907576SA (en) 2015-02-27 2019-09-27 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
US10881654B2 (en) 2015-04-24 2021-01-05 University Of Louisville Research Foundation, Inc. Selective PFKFB4 inhibitors for the treatment of cancer
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
TW201710250A (zh) * 2015-05-13 2017-03-16 賽爾維他股份公司 經取代之喹喏啉衍生物
WO2016191660A1 (en) * 2015-05-28 2016-12-01 University Of Louisville Research Foundation, Inc. Combinations of pfkfb3 inhibitors and immune checkpoint inhibitors to treat cancer
WO2017208174A2 (en) * 2016-05-31 2017-12-07 The Regents Of The University Of California Methods of treating disease with pfkfb3 inhibitors
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US10774046B2 (en) 2017-10-26 2020-09-15 University Of Louisville Research Foundation, Inc. Inhibitors for the treatment of cancer and related methods
SG11202011680YA (en) 2018-06-01 2020-12-30 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
EP3833345B1 (en) 2018-08-07 2024-07-17 Kemijski Institut Small molecule-inhibitors of 6-phosphofructo-1-kinase for reducing lactate generation by cancer cells
CN109535068B (zh) * 2018-12-26 2022-07-29 中国药科大学 吡啶取代查尔酮类化合物或其可药用的盐及其制备方法和用途
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
SMT202500481T1 (it) 2021-06-04 2026-01-12 Vertex Pharma N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio
LU102863B1 (en) 2021-10-19 2023-04-20 Kemijski Inst Small molecule-inhibitors of 6-phosphofructo-1-kinase for reducing Reactive oxygen species (ROS) generation by cancer cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046110A2 (en) * 1999-12-23 2001-06-28 The University Of Georgia Research Foundation, Inc. Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
WO2006037761A1 (en) * 2004-10-01 2006-04-13 Dac S.R.L. New histone deacetylases inhibitors
WO2006045010A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US20060035981A1 (en) 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046110A2 (en) * 1999-12-23 2001-06-28 The University Of Georgia Research Foundation, Inc. Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
WO2006037761A1 (en) * 2004-10-01 2006-04-13 Dac S.R.L. New histone deacetylases inhibitors
WO2006045010A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
JPN6013026052; ＲＯＢＩＮＳＯＮ，　Ｔ．　Ｐ．　ｅｔ　ａｌ: 'Ｓｙｎｔｈｅｓｉｓ　ａｎｄ　ｂｉｏｌｏｇｉｃａｌ　ｅｖａｌｕａｔｉｏｎ　ｏｆ　ａｒｏｍａｔｉｃ　ｅｎｏｎｅｓ　ｒｅｌａｔｅｄ　ｔｏ　ｃｕｒｃｕｍｉｎ' ＢＩＯＯＲＧＡＮＩＣ　＆　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ Ｖｏｌ．１３，　Ｎｏ．１２, 2005, ｐ．４００７-４０１３ *
JPN6013026055; ＳＩＬＶＡ，　Ｃ．　Ｈ．　Ｔ．　Ｐ．　ｅｔ　ａｌ: 'Ｍｏｌｅｃｕｌａｒ　ｄｙｎａｍｉｃｓ，　ｄａｔａｂａｓｅ　ｓｃｒｅｅｎｉｎｇ，　ｄｅｎｓｉｔｙ　ｆｕｎｃｔｉｏｎａｌ　ａｎｄ　ｄｏｃｋｉｎｇ　ｓｔｕｄｉｅｓ　ｏｆ　ｎｏｖｅｌ　ＲＡＲ　ｌｉｇａｎｄｓ' ＢＩＯＰＨＹＳＩＣＡＬ　ＣＨＥＭＩＳＴＲＹ Ｖｏｌ．１１７，　Ｎｏ．１, 2005, ｐ．７３-７７ *
JPN6013026059; ＫＡＴＲＩＴＺＫＹ，　Ａ．　Ｒ．　ｅｔ　ａｌ: 'ＱＳＡＲ　ｍｏｄｅｌｉｎｇ　ｏｆ　ａｎｔｉ-ｉｎｖａｓｉｖｅ　ａｃｔｉｖｉｔｙ　ｏｆ　ｏｒｇａｎｉｃ　ｃｏｍｐｏｕｎｄｓ　ｕｓｉｎｇ　ｓｔｒｕｃｔｕｒａｌ　ｄｅｓｃｒｉｐｔｏｒｓ' ＢＩＯＯＲＧＡＮＩＣ　＆　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ Ｖｏｌ．１４，　Ｎｏ．２０, 2006, ｐ．６９３３-６９３９ *
JPN7013002017; ＴＥＬＡＮＧ，Ｓ．　ｅｔ　ａｌ: 'Ｒａｓ　ｔｒａｎｓｆｏｒｍａｔｉｏｎ　ｒｅｑｕｉｒｅｓ　ｍｅｔａｂｏｌｉｃ　ｃｏｎｔｒｏｌ　ｂｙ　６-ｐｈｏｓｐｈｏｆｒｕｃｔｏ-２-ｋｉｎａｓｅ' Ｏｎｃｏｇｅｎｅ Ｖｏｌ．２５，　Ｎｏ．５５, 2006, ｐ．７２２５-７２３４ *
JPN7013002018; ＹＡＲＲＯＷ，　Ｊ．　Ｃ．　ｅｔ　ａｌ: 'ＰＨＥＮＯＴＹＰＩＣ　ＳＣＲＥＥＮＩＮＧ　ＯＦ　ＳＭＡＬＬ　ＭＯＬＥＣＵＬＥ　ＬＩＢＲＡＲＩＥＳ　ＢＹ　ＨＩＧＨ　ＴＨＲＯＵＧＨＰＵＴ　ＣＥＬＬ　ＩＭＡＧＩＮＧ' ＣＯＭＢＩＮＡＴＯＲＩＡＬ　ＣＨＥＭＩＳＴＲＹ　＆　ＨＩＧＨ　ＴＨＲＯＵＧＨＰＵＴ　ＳＣＲＥＥＮＩＮＧ Ｖｏｌ．６，　Ｎｏ．４, 2003, ｐ．２７９-２８６ *
JPN7013002019; ＩＲＩＫＵＲＡ，　Ｔ．　ｅｔ　ａｌ: 'ＡＮＴＩ　ＴＵＭＯＲ　ＡＣＴＩＶＩＴＹ　ＯＦ　３　ＳＵＢＳＴＩＴＵＴＥＤ　ＣＩＮＮＡＭＯＹＬ　ＰＹＲＩＤＩＮＥ　ＡＮＤ　１　ＯＸＩＤＥ' ＰＨＡＲＭＡＣＥＵＴＩＣＡＬ　ＳＯＣＩＥＴＹ　ＯＦ　ＪＡＰＡＮ Ｖｏｌ．１８，　Ｎｏ．７, 1970, ｐ．１４０８-１４１３ *
JPN7013002020; ＨＡＧＧＡＲＴＹ，　Ｓ．　Ｊ．　ｅｔ　ａｌ: 'Ｓｍａｌｌ　Ｍｏｌｅｃｕｌｅ　Ｍｏｄｕｌａｔｉｏｎ　ｏｆ　ｔｈｅ　Ｈｕｍａｎ　Ｃｈｒｏｍａｔｉｄ　Ｄｅｃａｔｅｎａｔｉｏｎ　Ｃｈｅｃｋｐｏｉｎｔ' ＣＨＥＭＩＳＴＲＹ　ＡＮＤ　ＢＩＯＬＯＧＹ Ｖｏｌ．１０，　Ｎｏ．１２, 2003, ｐ．１２６７-１２７９ *
JPN7013002021; ＫＡＵ，　Ｔ．　Ｒ．　ｅｔ　ａｌ: 'Ａ　ＣＨＥＭＩＣＡＬ　ＧＥＮＥＴＩＣ　ＳＣＲＥＥＮ　ＩＤＥＮＴＩＦＩＥＳ　ＩＮＨＩＢＩＴＯＲＳ　ＯＦ　ＲＥＧＵＬＡＴＥＤ　ＮＵＣＬＥＡＲ　ＥＸＰＯＲＴ　ＯＦ　Ａ　ＦＯＲＫＨＥＡＤ　ＴＲＡＮＳＣＲＩＰＴ' ＣＡＮＣＥＲ　ＣＥＬＬ Ｖｏｌ．４，　Ｎｏ．６, 2003, ｐ．４６３-４７６ *
JPN7013002022; ＮＡＭ，　Ｎ．-Ｈ．　ｅｔ　ａｌ: 'Ｓｙｎｔｈｅｓｉｓ　ａｎｄ　ｃｙｔｏｔｏｘｉｃｉｔｙ　ｏｆ　２，５-ｄｉｈｙｄｒｏｘｙｃｈａｌｃｏｎｅｓ　ａｎｄ　ｒｅｌａｔｅｄ　ｃｏｍｐｏｕｎｄｓ' ＡＲＣＨＩＶＥＳ　ＯＦ　ＰＨＡＲＭＡＣＡＬ　ＲＥＳＥＡＲＣＨ Ｖｏｌ．２７，　Ｎｏ．６, 2004, ｐ．５８１-５８８ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512398A (ja) * 2012-03-29 2015-04-27 アドヴァンスト キャンサー セラピューティクス エルエルシーＡｄｖａｎｃｅｄ Ｃａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ Ｐｆｋｆｂ２阻害剤および抗癌治療法としての使用方法

Also Published As

Publication number Publication date
WO2008156783A3 (en) 2009-07-16
EP2167058B1 (en) 2015-08-12
EP2167058A2 (en) 2010-03-31
US8088385B2 (en) 2012-01-03
AU2008266856A1 (en) 2008-12-24
US20090074884A1 (en) 2009-03-19
WO2008156783A2 (en) 2008-12-24
AU2008266856A2 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
US8088385B2 (en) PFKB3 inhibitor for the treatment of a proliferative cancer
US8557823B2 (en) Family of PFKFB3 inhibitors with anti-neoplastic activities
Peng et al. Altered glycolysis results in drug-resistant in clinical tumor therapy
Ganapathy-Kanniappan et al. 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy
Chen et al. Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway
CN103442705B (zh) 用于治疗癌症和免疫抑制的昔洛舍平与线粒体抑制剂的组合
US11596613B2 (en) Compositions and methods for treating cancer
KR20110132446A (ko) 키나아제 단백질 결합 억제제
Zhao et al. Glycolytic inhibition with 3-bromopyruvate suppresses tumor growth and improves survival in a murine model of anaplastic thyroid cancer
JP7854213B2 (ja) ミトコンドリア標的化及び抗癌治療のためのアルキルｔｐｐ化合物
Liu et al. Oridonin inhibits bladder cancer survival and immune escape by covalently targeting HK1
KR20200069365A (ko) 미토플라보신: 플라빈-함유 효소를 표적화하여 미토콘드리아 호흡 억제에 의해 암 줄기 세포(cscs)를 제거함
JP2020513024A (ja) リンゴ酸−アスパラギン酸シャトル抑制剤および抗癌剤を有効成分として含有する癌の予防および治療用薬学的組成物
JP2011516473A (ja) 医薬組成物
Nishioka et al. Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1
KR20180101329A (ko) 암 치료에 사용하기 위한 헤테로시클릭 pdk1 억제제
Qayyum et al. Design, synthesis and preclinical evaluations of (s)-2-((s)-1-benzyl-2, 5-dioxopyrrolidin-3-yl)-3-(4-isopropylphenyl)-2-methylpropanal (succ-5) as cardioprotective, hepatoprotective and lipid lowering molecule. in-vivo and in-silico approaches
CA2717511A1 (en) Modulation of enzymatic structure, activity, and/or expression level
Ma et al. Salvianolic acid A targets glutamic-oxaloacetic transaminase 2 to ameliorate doxorubicin-induced myocardial oxidative injury by activating malate-aspartate NADH shuttle
Tsubaki et al. Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells.
US20090082304A1 (en) Methods of Treating Hematological Malignancies with Nucleoside Analog Drugs
Ye et al. Ammonium metabolism rewiring in the prostate cancer microenvironment: Mechanisms and clinical prospects
Qi et al. Nicotinamide ribose prevents diabetic cardiomyopathy through promoting TET2-mediated active DNA demethylation in STZ-induced diabetic mice heart
Zhou Exploiting Glucose Metabolic Vulnerabilities to Enhance Cancer Therapies
KR20190015942A (ko) 골 질환 예방 또는 치료용 화합물 및 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131105